Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries Portfolio News / By Karina Tin February 2, 2021 Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries Read More »
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders Portfolio News / By Karina Tin January 21, 2021 Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders Read More »
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology Portfolio News / By Karina Tin January 12, 2021 NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Portfolio News / By Karina Tin January 11, 2021 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Read More »
eFFECTOR Appoints Mike Byrnes as Chief Financial Officer Portfolio News / By Karina Tin January 7, 2021 eFFECTOR Appoints Mike Byrnes as Chief Financial Officer Read More »
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer Portfolio News / By Karina Tin January 7, 2021 Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer Read More »
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies Portfolio News / By Karina Tin January 7, 2021 Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies Read More »
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock PDF Version Portfolio News / By Karina Tin January 5, 2021 NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock PDF Version Read More »
A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers Portfolio News / By Karina Tin December 23, 2020 A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers Read More »
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 Portfolio News / By Karina Tin December 21, 2020 ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 Read More »
